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A synthetic cell permeable 
antioxidant protects neurons 
against acute oxidative stress
Nicola J. Drummond1, Nick O. Davies2, Janet E. Lovett3, Mark R. Miller4, Graeme Cook5, 
Thomas Becker2, Catherina G. Becker2, Donald B. McPhail5 & Tilo Kunath  1
Excessive reactive oxygen species (ROS) can damage proteins, lipids, and DNA, which result in cell 
damage and death. The outcomes can be acute, as seen in stroke, or more chronic as observed in age-
related diseases such as Parkinson’s disease. Here we investigate the antioxidant ability of a novel 
synthetic flavonoid, Proxison (7-decyl-3-hydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone), using 
a range of in vitro and in vivo approaches. We show that, while it has radical scavenging ability on par 
with other flavonoids in a cell-free system, Proxison is orders of magnitude more potent than natural 
flavonoids at protecting neural cells against oxidative stress and is capable of rescuing damaged cells. 
The unique combination of a lipophilic hydrocarbon tail with a modified polyphenolic head group 
promotes efficient cellular uptake and moderate mitochondrial enrichment of Proxison. Importantly, in 
vivo administration of Proxison demonstrated effective and well tolerated neuroprotection against cell 
loss in a zebrafish model of dopaminergic neurodegeneration.
Oxidative stress has been implicated in a wide range of age-related conditions, including heart disease, cancer, 
diabetes and neurodegenerative diseases1–4. In healthy cells there is a balance between the production of reactive 
oxygen species (ROS) and their removal by antioxidants, with discrete generation of ROS playing an essential role 
regulating cell signaling and function5,6. Excessive production of ROS results in oxidative stress causing aberrant 
cell signaling, damage to cellular components, and subsequent disease. A number of ROS are involved in cellular 
oxidative stress, including superoxide radicals, hydrogen peroxide and hydroxyl radicals. The chemical reactivity 
of each of these and their site of production within the cell determines their ability to damage cellular compo-
nents7,8. Mitochondria produce superoxide radicals and hydrogen peroxide as by-products of oxygen consump-
tion. There are multiple sites of superoxide production in the mitochondrial electron transport chain including 
NADH-ubiquinone oxidoreductase of complex I, the coenzyme Q pool as well as complexes II and III9–13. Acute 
increased superoxide production at complex I occurs in stroke through a conserved mechanism14,15. This results 
in oxidative damage and neuronal cell death by mechanisms that include increased H2O2 release16,17.
Chronic exposure to oxidative stress has been implicated in numerous age-related degenerative conditions, 
including Parkinson’s disease where age is the most significant risk factor. Post-mortem analysis of Parkinson’s 
patients brains showed evidence of oxidative damage and mitochondrial complex I dysfunction in the substantia 
nigra3,18–21. During earlier stages of Parkinson’s disease, patients also show evidence of mitochondrial dysfunction 
and oxidative damage in their platelets and plasma22,23. However, it is difficult to determine when in the disease 
process this damage occurs and how influential it is in disease progression. The use of novel potent antioxidants 
in combination with refined disease models will be key to definng the role for oxidative stress in disease patho-
genesis, and to pinpoint when and where this occurs. If it proves to be an early and pivotal defect, it opens up an 
exciting new field of potential therapeutic targets for intervention of age-related diseases.
Flavonoids are a large group of polyphenolic antioxidant compounds found in plants that can directly scavenge 
ROS. Their antioxidant activity is a result of the efficiency by which they can donate hydrogen atoms from their 
multiple hydroxyl groups to free radicals, a mechanism that is facilitated by the extended conjugation afforded 
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through the π-electron system of the core flavonoid molecular scaffold24,25. The dietary flavonoids, quercetin and 
myricetin are amongst the most potent24–26, although they are poorly absorbed from the diet27–29. Furthermore, 
their physicochemical attributes mitigate against effective uptake and distribution in the cell25. However, cell 
absorption characteristics and bioactivity can be improved significantly by chemical modification of the par-
ent myricetin compound through attachment of lipophilic alkyl chains of different lengths and by removal of 
hydroxyl groups that do not contribute to the antioxidant potential. A rational drug design approach, based 
on structure-activity relationships of natural and modified flavonoid antioxidants led to Proxison (7-decyl-3-
hydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone) as one of the most promising of these synthetic com-
pounds29. This compound comprises of a straight chain C10 hydrocarbon tail covalently linked to a flavonoid 
head group similar to myricetin (Fig. 1a). In terms of prevention of lipid peroxidation, Proxison exhibited supe-
rior protection when compared to structurally similar compounds30. Recently, Proxison was shown to reduce 
proliferation of a breast cancer cell line at high concentrations, but its antioxidant functions at physiological 
concentrations have not been investigated31.
The aim of this study was to examine the antioxidant and cell protective activity of Proxison using in vitro and 
in vivo model systems. This compound had potent radical scavenging capabilities in a cell-free radical scavenging 
model and was highly protective in a neuronal cell model of acute oxidative stress. In vivo, Proxison efficiently 
protected against 6-hydroxydopamine (6-OHDA) induced death of dopaminergic neurons in a zebrafish model. 
We demonstrate that Proxison is highly cell permeable and shows enrichment in the cytosol, especially to mito-
chondria, a key characteristic that may be critical for its protective function in neurons. Therefore, Proxison 
represents a novel class of synthetic antioxidant, which is well tolerated and effective in promoting cell survival in 
conditions where oxidative stress is the major cause of cell death.
Results
Radical scavenging capabilities of flavonoid antioxidants. To directly compare the scavenging ability 
of Proxison to the structurally related natural flavonoids, myricetin and quercetin (Fig. 1a), we used the stable 
free radical galvinoxyl in a cell-free assay. Galvinoxyl has one unpaired electron, which is extensively delocalised 
throughout the molecule and gives rise to a characteristic electron paramagnetic resonance (EPR) spectrum as a 
result of the interaction of the electron spin with the nuclear spins of protons in the molecule. All three flavonoids 
efficiently scavenged galvinoxyl radicals in this chemical model system and mediated a concentration-depend-
ent reduction in EPR signal intensity (Fig. 1b,c). The radical scavenging ability of Proxison was equal to that of 
myricetin despite having two less hydroxyl groups and increased hydrophobicity, and both compounds were 
more than twice as potent as quercetin, which has one less hydroxyl group than myricetin on the B-ring (Fig. 1d).
Protection against acute oxidative stress in cells. Next, we compared Proxison to myricetin, quercetin, 
and other antioxidants for their ability to protect against oxidative stress in a neural cell culture model, SH-SY5Y 
neuroblastoma cells. These cells were treated with the organic peroxide tert-butyl hydroperoxide (tBHP) to gen-
erate peroxyl radicals and cause acute oxidative stress32. Cells exhibited a significant reduction in cell metabolic 
activity (MTS tetrazolium reduction assay) after 5 h treatment with 200–800 μM tBHP (Supplementary Figure 1). 
400 μM tBHP was found to be optimal as it elicited a robust and reproducible stressor effect in this cell-based 
assay.
Proxison used at 5 and 10 μM significantly prevented the reduction in cell metabolic activity caused by 400 μM 
tBHP treatment (Fig. 2a). Due to its strong reducing capabilities, concentrations above 50 μM Proxison caused 
Figure 1. Chemical structures and radical scavenging ability of antioxidants. (a) The chemical structures of 
Proxison, myricetin, and quercetin. (b,c) Galvinoxyl EPR spectra in the absence or presence of 2.5 μM (b) or 
5 μM (c) antioxidants. (d) The percentage of the galvinoxyl radical remaining after incubation with 2.5 μM or 
5 μM of Proxison, myricetin and quercetin.
www.nature.com/scientificreports/
3SCIeNTIFIC REPORTS | 7: 11857  | DOI:10.1038/s41598-017-12072-5
signs of cytotoxicity. Quercetin showed significant protection between 25–100 μM, however, a 10-fold higher 
concentration was required to exert a level of protection similar to Proxison. In contrast, myricetin showed no 
appreciable protection against tBHP even at 100 μM. Other antioxidants, including vitamin E, Idebenone (a syn-
thetic derivative of coenzyme Q10) and coenzyme Q10 showed no protection in this assay (Fig. 2a). Furthermore, 
morphological signs consistent with lipid peroxidation, including membrane blebbing, which were observed by 
5 h of tBHP treatment, were rescued by Proxison and high-dose quercetin, but not myricetin (Fig. 2b).
Oxidative stress can also result in cytotoxicity, so we next assessed cell death by the lactate dehydrogenase 
(LDH) assay. tBHP treatment of SH-SY5Y cells for 16 h caused a significant deterioration of cell membrane integ-
rity resulting in leakage of cytoplasmic LDH into the media. Proxison (5–10 μM) and a high concentration of 
quercetin (100 μM, but not 25 μM) significantly prevented the cytotoxic effects of tBHP, while myricetin and vita-
min E offered no protection (Fig. 2c). Similarly, we further confirmed the cytoprotective capabilities of Proxison 
with a propidium iodide (PI) exclusion assay (Fig. 2d). Less than 30% of tBHP-treated cells were viable after 
16 hours as determined by this assay. However, pre-incubation with Proxison at 10 μM, but not 1 μM, protected 
against cell death to levels that were not significantly different from non-treated control cells (Fig. 2d).
We further confirmed the protective capabilites of Proxison with an independent clone of SH-SY5Y cells 
(Supplementary Movies 1 and 2), and demonstrated that 1 μM Proxison was sufficient to protect these cells from 
tBHP induced cell death (Supplementary Figure 2). We also compared Proxison, myricetin, and quercetin for 
Figure 2. Antioxidant protection against acute oxidative stress. (a) Metabolic activity of SH-SY5Y cells treated 
with 400 μM tBHP for 4 hours in the absence or presence of differing concentrations of 6 antioxidants (n = 3). 
(b) Phase-contrast microscopy of tBHP-treated SH-SH5Y cells treated with DMSO (vehicle), myricetin, 
quercetin, or Proxison. Scale bar: 75 μm. (c) tBHP-induced cytotoxicity was determined at 16 hours with the 
LDH assay in the absence or presence of 4 antioxidants (n = 3). (d) The percentage of dead cells was assessed 
at 16 hours by PI FACS analysis for Proxison-treated cells (n = 2). ANOVA with a Tukey’s post-hoc test was 
performed to assess the significant difference between antioxidant-treated and vehicle-treated cells in (a), (c), 
and (d); **p < 0.01, ***p < 0.001.
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their ability to protect a completely different neural cell line, Neuroscreen-1™ (NS-1), from peroxide induced 
toxicity. Similar to the SH-SY5Y results, a low dose of Proxison (0.5–5 μM) or a high dose of quercetin (25–50 μM) 
could protect NS-1 cells from tBHP-induced cytotoxicity, while myricetin did not exhibit any protective proper-
ties in this cell culture model (Supplementary Figure 3).
Flavonoid antioxidant cellular uptake and intracellular localisation. Given that the antioxidants 
were similarly potent in the cell-free galvinoxyl assay, the differential protective properties of Proxison, quercetin 
and myricetin in cells could be due to differences in cellular uptake or subcellular localisation. To investigate the 
intracellular uptake and localisation of the different flavonoids we took advantage of the endogenous fluorescence 
characteristics of these molecules33,34. Intrinsic green fluorescence of Proxison, myricetin and quercetin was con-
firmed using a plate reader with excitation 485 nm and emission 520 nm (Supplementary Figure 4).
Cells were incubated with Proxison (10 μM), quercetin (100 μM), or myricetin (100 μM) for 2 h and washed 
out before processing for confocal imaging. Whereas quercetin accumulated in nuclei, Proxison was localised 
to the cytoplasm with some enrichment in filamentous perinuclear structures (Fig. 3a). The subcellular locali-
sation of Proxison was investigated further by staining with the mitochondrial marker, Mitotracker Deep Red. 
Although Proxison was observed throughout the cytoplasm, the stronger filamentous staining co-localized with 
Mitotracker Deep Red suggesting some form of enrichment at mitochondria (Fig. 3b). Despite an emission pro-
file similar to quercetin (Supplementary Figure 4), myricetin did not appear to be taken up into cells, as the 
fluorescence observed in treated cells was similar to the background in control cells (Fig. 3a). Cellular uptake was 
further investigated by FACS analysis, which showed significant intracellular levels of Proxison and quercetin, 
whereas myricetin was undetectable (Fig. 3c). This suggests the lack of protective activity of myricetin compared 
to Proxison and quercetin reflects its inability to enter cells. In summary, Proxison was efficiently taken up by cells 
and was localised to the cytoplasm with moderate enrichment to mitochondria.
Given that Proxison exhibited some co-localization with a mitochondrial marker, we decided to test its protec-
tive capabilities directly against a known mitochondrial antioxidant, MitoQ35. As determined by the LDH release 
assay, both Proxison and MitoQ at 10 μM significantly protected cells against a high-dose of tBHP (400 μM), and 
Proxison was at least twice as potent as MitoQ in this acute cytotoxicity assay (Fig. 3d).
Proxison prevents intracellular radical production and downstream effects of oxidative 
stress. To assess intracellular scavenging potency of Proxison, the ROS biosensor CellROX® Deep Red was 
used36. Using far-red fluorescence intensity as a read-out of radical production, tBHP was found to significantly 
increase intracellular ROS in SH-SY5Y cells, and Proxison and quercetin, but not myricetin, were capable of 
preventing this ROS production (Fig. 4a). Quantification of far-red signals confirmed Proxison and high-dose 
quercetin effectively blocked the accumulation of tBHP-generated radicals to the level of untreated cells (Fig. 4b).
A major mechanism in the cellular defense against oxidative stress involves activation of the Nrf2-Keap1 
antioxidant response signaling pathway35. This requires nuclear localization of a key transcription factor NRF2 to 
activate a number of antioxidant genes37–39. To determine whether Proxison is capable of preventing downstream 
consequences of tBHP induced oxidative stress we analysed subcellular localisation and action of NRF2. Nuclear 
NRF2 increased upon tBHP treatment, an effect that was significantly prevented in the presence of Proxison 
(Fig. 5a,b). To confirm NRF2 was active in the nucleus, we quantified expression of two NRF2-regulated antioxi-
dant response element (ARE) genes, NQO1 and HMOX1. The increased transcription of both ARE genes caused 
by tBHP treatment was significantly attenuated by Proxison (Fig. 5d). The transcript levels of NRF2 itself were 
unaffected agreeing with the known post-translational mechanism of action for this transcription factor39.
To determine whether Proxison protects against ROS-induced oxidative damage of nucleic acids, we looked 
for the presence of 8-hydroxy-2’-deoxyguanosine (8-OHdG) in the cell, a marker of oxidative damage to DNA 
and RNA. 8-OHdG is a major product of nucleic acid oxidation and its concentrations within a cell act as a 
read-out of oxidative stress induced damage40. Proxison was able to completely inhibit the accumulation of 
8-OHdG marks in cells caused by tBHP treatment (Fig. 5a,c).
Proxison protects dopaminergic neurons in a zebrafish model. To determine the ability of Proxison 
to protect neurons in an intact animal and to detect potential toxic side-effects, we assessed its ability to pro-
tect dopaminergic neurons in the brain of zebrafish embryos. The neurotoxic compound 6-hydroxydopamine 
(6-OHDA) was used to selectively induce death of dopaminergic and noradrenergic neurons in this model, 
as measured by counts of tyrosine hydroxylase (TH) positive neurons41,42. At 24 hours post fertilisation (hpf), 
zebrafish embryos were treated with 6-OHDA (250 μM for 24 h) in the absence or presence of the antioxidants 
Proxison or quercetin. At 48 hpf embryos were fixed and immunostained for TH prior to collection of z-stack 
images of each embryo head by confocal microscopy (Fig. 6a), and the number of TH positive cells were quanti-
fied (Fig. 6b). Embryos treated with 6-OHDA consistently had 30% less TH positive cells than control embryos, 
while co-incubation with Proxison showed significant protection against 6-OHDA-induced neuronal cell loss 
(Fig. 6a,b). Quercetin also afforded protection against 6-OHDA induced toxicity, but was less robust than 
Proxison. None of the treatments reduced survival or perturbed normal development of the embryos, showing 
that Proxison was not toxic and was well tolerated at the concentrations used that elicited neuroprotective effects 
in vivo.
Discussion
Here we characterise the antioxidant profile of a novel synthetic flavonoid, Proxison. Although the intrinsic rad-
ical scavenging activity of Proxison is similar to its natural counterparts, it possesses a superior ability to protect 
against acute oxidative stress in cellular contexts. The lipophilic tail of Proxison enhances its cellular uptake and 
may improve its stability30. The subcellular localization of Proxison is mostly cytoplasmic with some enrichment 
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Figure 3. Cellular uptake and subcellular localisation of antioxidants. (a) Confocal microscopy of SH-SY5Y 
cells incubated with Proxison, quercetin, myricetin or DMSO (vehicle) before fixing and counterstaining with 
DAPI (blue). Scale bar: 11 μm. (b) Subcellular localisation of Proxison was assessed by co-incubation with 
Mitotracker Deep Red prior to fixation and confocal imaging. Scale bar: 11 μm. (c) Representative FACS plots 
of SH-SY5Y cells incubated with Proxison, quercetin, myricetin or DMSO (vehicle) for 2 hours. Mean green 
fluorescence of live cells incubated with each antioxidant showed a significant uptake of Proxison and quercetin 
(n = 2). (d) Proxison or MitoQ at 10 μM significantly rescued cytotoxicity due to tBHP treatment (p < 0.01), but 
Proxison was significantly more effective than MitoQ when directly compared (p < 0.05). ANOVA with a post-
hoc Tukey test was performed; *p < 0.05, **p < 0.01, ***p < 0.001.
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at mitochondria, while quercetin localizes to the nucleus. Although myricetin was as potent as Proxison in a 
cell-free radical scavenging assay, it was poorly taken up by cells, possibly due to its instability at neutral pH or 
its low lipophilicity43,44. Quercetin was a less potent antioxidant scavenger in the cell-free assay, but it was readily 
taken up by cells, and it accumulates in the nucleus for, as yet, unknown reasons33. This localization could explain 
why a 10-fold higher concentration of quercetin is needed to provide a similar level of protection as Proxison, 
which is cytoplasmic, against tBHP-induced toxicity. The superior potency of Proxison may also be due to the 
phenoxyl radical (the oxidized form of Proxison) being recycled by intracellular antioxidants, or other reduc-
tive pathways, back to Proxison, as occurs for vitamin E45. Flavonoid antioxidants are also capable of chelating 
transition metal ions such as iron or copper thereby limiting the breakdown of tBHP to its initiating free radical 
products or inhibiting lipid peroxidation through the Fenton reaction25. Proxison may therefore be able to exert 
a protective effect by diverse mechanisms beyond the direct scavenging of free radicals by hydrogen atom elec-
tron transfer reactions, a model supported by structure-activity studies on a wide range of flavonoids, including 
myricetin46.
We demonstrated that Proxison scavenges intracellular ROS and prevents downstream oxidative damage to 
both membranes and nucleic acids. Induction of the NRF2 antioxidant response pathway was significantly damp-
ened by Proxison, but not eliminated. Therefore, Proxison can act in conjunction with other cellular antioxidant 
responses to acute oxidative stress to promote cell survival. Importantly, the studies in zebrafish embryos showed 
that Proxison, and to a lesser extent quercetin, is capable of protecting dopaminergic neurons against acute neu-
ronal loss in an intact animal. It is important to demonstrate that this neuronal loss is due to oxidative stress 
induced by 6-OHDA, and zebrafish models that directly measure oxidative stress in embryos have recently been 
established47.
There are currently several published classes of synthetic mitochondrial-targeted antioxidants. The Mito com-
pounds contain a triphenylphosphonium ion (TPP), which has a positive charge that attracts it to the mito-
chondrial matrix. The TPP ion has been attached to a number of known antioxidants, including vitamin E and 
coenzyme Q1035,48. MitoQ compounds are taken up into cells and accumulate in mitochondria only when the 
membrane potential is intact, which may not always be the case in damaged cells35,48,49. MitoQ was tested in a 
phase II clinical trial for symptomatic Parkinson’s disease patients. However, there was no change in the rate 
of disease progression50. Currently MitoQ is due to undergo a phase II clinical trial for chronic kidney disease 
Figure 4. Intracellular scavenging of tBHP-induced radicals by antioxidants. (a) Intracellular ROS production 
in SH-SY5Y cells treated with tBHP in the absence or presence of Proxison (10 μM), quercetin (100 μM), or 
myricetin (100 μM) was observed with CellROX® Deep Red. Scale bar: 40 μm. (b) The average intensity of 
CellROX® Deep Red (far red) fluorescence of cells in the five conditions were quantified with Volocity software. 
Bars represent the mean from four independent experiments with duplicate cover slips for Proxison, and two 
independent experiments for quercetin and myricetin. Error bars represent the SEM. ANOVA with the post-
hoc Tukey test was performed to assess significant difference to vehicle-treated cells; **p < 0.01, ***p < 0.001.
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(ClinicalTrials.gov Identifier: NCT02364648). SS peptides are short positively charged peptides that are cell 
permeable and localise to mitochondria51,52. SS peptide localization is due to their lipophilicity and positive 
charge and is partially reliant on an intact mitochondrial membrane potential52,53. The lead SS peptide, SS-31 
(Bendavia; MTP-131), is protective in rodent models of amyotrophic lateral sclerosis and myocardial infarc-
tion54,55. Bendavia is currently in clinical trials for heart failure (ClinicalTrials.gov Identifier: NCT02388464) and 
genetically confirmed mitochondrial disease (ClinicalTrials.gov Identifier: NCT02805790). The plant-derived 
antioxidants, plastoquinone and thymoquinone, have also been modified to accumulate in mitochondria56. These 
mitochondrially-targetted antioxidants show protection in a rat stroke model57. Proxison exhibits some mito-
chondrial enrichment as a likely consequence of the lipophilicity of a long hydrocarbon tail combined with the 
unique redox properties of the polyphenolic head group58. However, it is not yet known whether this enrichment 
is due to the unique properties of mitochondrial lipids or proteins that may have affinity for Proxison, or if the 
enrichment requires an intact mitochondrial membrane potential.
This novel antioxidant can be applied to investigate oxidative stress in disease models, like α-synucleinopathies 
and other neurodegeneration models. This would provide insight into disease processes and aid in development 
Figure 5. Proxison reduces tBHP-induced NRF2 oxidative stress response and prevents 8-OHdG DNA 
oxidative damage. (a) tBHP-treated SH-SY5Y cells in the absence or presence of Proxison were fixed and 
immunostained for NRF2 (red), 8-OHdG (green), and counterstained for the nuclear marker DAPI (blue). 
Scale bar: 60 μm. (b,c) The intensity of NRF2 red fluorescence (b) and 8-OHdG green fluorescence (c) in the 
nuclei as quantified using ImageJ. Bars in (b) and (c) represent the mean of three coverslips from independent 
experiments (n = 3) with 2–4 images per coverslip, error bars represent the SEM. (d) RNA was extracted 
from similarly treated cells to measure gene expression of NRF2, NQO1 and HMOX1 relative to TATA-
binding protein (TBP). Bars represent the mean of duplicate or triplicate wells (n = 2–3). Error bars represent 
the standard deviation. ANOVA with the Tukey’s post-hoc test was performed in (b), (c) and (d) to assess 
significant difference to vehicle-treated cells; *p < 0.05, ***p < 0.001.
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of novel treatments. In addition, Proxison could have applications for regenerative medicine where oxidative 
stress has been implicated in poor cell survival of transplanted cells, with the advantage that the molecule can be 
pre-loaded into cells prior to transplantation. Proxison could also have applications for conditions, such as stroke 
or cardiac infarction, in which a temporary, but acute, exposure to oxidative stress is experienced, as well as dis-
eases in which oxidative stress and mitochondrial dysfunction are core features.
Methods
Galvinoxyl Electron Paramagnetic Resonance Spectroscopy. Galvinoxyl (182 μM, Sigma) was 
mixed with 2.5 μM or 5 μM Proxison (7-decyl-3-hydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone, Antoxis), 
myricetin (Sigma) or quercetin (Sigma) in DMSO. Five minutes after addition measurements were taken 
using the Magnettech Miniscope MS200 EPR machine. Settings: centre field = 3364.05 G; Sweep = 69.59 G; 
Sweep Time = 20 s; Smooth = 0 s; Steps = 4096; Number of passes = 1 pass; Modulation = 1.5 G; Power = 7 dB; 
Gain = 1E2. The percentage radical scavenging ability was calculated from the EPR signal intensity with antioxi-
dant relative to the signal intensity of galvinoxyl alone.
Cell Culture. The SH-SY5Y cell line was a kind gift from Professor David Porteous (Institute of Genetics 
and Molecular Medicine, University of Edinburgh). They were cultured at 37 °C in a humidified atmosphere of 
5% CO2 in DMEM supplemented with 10% FBS, 2 mM L-glutamine and 1 mM sodium pyruvate (all from Life 
Technologies). When cells were 70–80% confluent they were passaged using trypsin (Life Technologies). An inde-
pendent clone of SH-SY5Y cells was kindly provided by Dr Michael J Devine (Institute of Neurology, UCL). The 
rat Neuroscreen™-1 (NS-1) cells (Thermo Scientific, R04–0001-AP) were cultured in NS-1 medium consisting of 
RPMI 1640 basal medium (Hyclone, SH30027) supplemented with 10% horse serum (Life Technologies, 26050-
088), 5% FBS and 2 mM L-glutamine.
MTS Assay. The MTS assay was performed using the Promega CellTiter 96® Aqueous MTS Reagent Powder 
(Promega) with phenazine methosulphate (PMS; Sigma) as the electron coupler. SH-SY5Y cells were seeded 
at 1.25 × 105 cells/cm2 in 96-well plates and incubated for 24 hours when either tBHP (Sigma) was added or 
cells were pre-incubated with antioxidants Proxison, myricetin, quercetin (all from Antoxis), vitamin E (Sigma), 
Idebenone (Antoxis) or coenzyme Q10 (Sigma) for 30 minutes before tBHP (400 μM) addition. Five hours 
later phase-contrast images were collected with an Olympus IX51 inverted microscope and the MTS assay was 
Figure 6. Antioxidant protection against 6-OHDA-induced dopaminergic cell death in zebrafish embryos. (a) 
Zebrafish embryos at 24 hours post-fertilisation (hpf) were treated with 6-OHDA for 24 hours in the presence or 
absence of the antioxidants Proxison or quercetin (10 μM). Embryos were then fixed at 48 hpf, immunostained 
for TH (red) and confocal images were taken of the embryo head viewed from the top. Scale bar: 50 μm. (b) The 
number of TH-positive cells in each embryo was counted for each treatment group (control, n = 28; vehicle, 
n = 30; Proxison, n = 26, quercetin, n = 24). Bars represent the mean number of TH-positive cells and error 
bars show the SEM. ANOVA with Tukey’s post-hoc test was performed to assess the significant difference to the 
6-OHDA treated embryos; *p < 0.05, ***p < 0.001.
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performed, according to manufacturer’s instructions. Briefly, 100 μl of PMS (0.92 mg/ml) was added to 2 ml of 
MTS (2 mg/ml), and then 20 μl of the MTS/PMS mixture was added to each well of a 96-well plate containing 
100 μl of conditioned media. The plate was incubated at 37 °C/5% CO2 for 1 hour when the absorbance at 490 nm 
was measured using the FLUOstar OMEGA microplate reader (BMG LabTech). The background absorbance 
from the media incubated with MTS/PMS was subtracted from the well absorbance to give the sample absorb-
ance. The percentage of the sample absorbance relative to control treated cells absorbance gave the % metabolic 
activity. NS-1 cells were seeded at 3.125 × 104 cells/cm2 on 6 μg/cm2 collagen I coated 96-well plates, and differ-
entiation was initiated the following day medium by replacing medium with a 1 in 10 dilution of NS-1 medium 
supplemented with 50 ng/ml nerve growth factor β (NGFβ) (Sigma, N2513). On day 3 of differentiation cells were 
treated with tBHP (200 μM) for 16 hours before an MTS assay was performed as described above.
LDH Assay. The LDH-Cytotoxicity Assay Kit II (Source Bioscience) was used to quantify cell death due to 
tBHP treatment. SH-SY5Y cells were pre-incubated with Proxison, myricetin, quercetin, vitamin E, or MitoQ 
(gift from Prof Mike Murphy) for 30 minutes when 400 μM tBHP was added to the antioxidants for 16 hours. 
Thirty minutes before the end of tBHP treatment cell lysis buffer was added to the high control wells. At the end 
of tBHP treatment the 96-well plate was gently mixed to distribute the LDH in the media. The plate was then 
centrifuged at 600 g for 10 minutes to precipitate cells and debris. 10 μl of media from each well was moved to a 
new 96-well plate and 100 μl of LDH reaction mix was added to each well. The plate was then incubated at room 
temperature for 30–60 minutes when absorbance was read using the FLUOstar OMEGA microplate reader. The 
650 nm reference absorbance was subtracted from the 450 nm absorbance reading to give the well absorbance. 
The background absorbance was subtracted from the well absorbance to give the sample absorbance. The sample 
absorbance was subtracted from control-cultured cells (low control) and divided by the cells that had been lysed 
(high control) minus the control cells (low control) to give the % cytotoxicity.
PI FACS. The propidium iodide (PI) assay was performed to assess Proxison protection against tBHP-induced 
toxicity. SH-SY5Y cells were pre-incubated with Proxison (1 or 10 μM) for 30 minutes when 400 μM tBHP was 
added for 16 hours. Then the media was collected and cells were lifted using trypsin, washed in PBS with 2% FBS 
and resuspended in 100 μl PBS with 2% FBS. This cell solution was filtered and incubated with PI (1 μg/ml) at 
room temperature for 10 minutes. Then 300 μl PBS with 2% FBS was added to dilute the cells. Cells were kept on 
ice until FACS analysis data was collected using the FACS Calibur and post-acquisition analysis was performed 
using FlowJo X. The unstained sample was used to create gates to determine PI positive cells and the percentage 
of PI positive and negative cells was calculated.
Videomicroscopy. Live cell imaging of SH-SY5Y cells treated with tBHP (400 μM) in the absence or pres-
ence of Proxison (1 μM) was obtained with the Cell-IQ system (CM Technologies) for 5 hours (Supplementary 
Movies 1 and 2).
Antioxidant Fluorescence. Proxison, myricetin and quercetin (1 mM) in DMSO were added to a 96-well 
plate in triplicate. The intrinsic fluorescence of each compound was measured using a FLUOstar OMEGA 
microplate reader (BMG LabTech) with excitation 485 nm and emission 520 nm. DMSO background fluores-
cence was subtracted.
Antioxidant Subcellular Localisation. SH-SY5Y cells were seeded on coverslips and loaded with the 
following antioxidants for 2 hours; 10 μM Proxison, 100 μM quercetin, 100 μM myricetin or DMSO as a vehi-
cle control. Then cells were fixed in 4% PFA (Sigma) and counterstained with 4′,6-diamidino-2-phenylindole 
(DAPI; Life Technologies) for 10 minutes. Coverslips were washed in MilliQ water and mounted onto slides 
using Vectashield (Vector Laboratories, H1000). Images were taken using the 63x objective of the Leica TCS SPE 
confocal microscope. The 488 nm laser was used to excite the antioxidants and emission was measured between 
496–595 nm. To observe Proxison subcellular localization, SH-SY5Y cells on coverslips (as above) were loaded 
with 100 nM Mitotracker Deep Red (Life Technologies) for 20 minutes before the addition of 10 μM Proxison 
for 2 hours. The cells were then fixed in 4% PFA and processed as described above. The 635 nm laser was used to 
excite Mitotracker Deep Red.
Intracellular Antioxidant Fluorescence (FACS). SH-SY5Y cells were treated as above for antioxidant 
localisation but 2 hours after antioxidant addition cells were lifted using trypsin, washed in PBS with 2% FBS and 
resuspended in 100 μl PBS with 2% FBS. The cell solution was then filtered and cells were incubated with PI (1 μg/
ml) on ice. 300 μl PBS with 2% FBS was added. Cells were kept on ice until fluorescence was analysed using the 
FACS Calibur. Post-acquisition analysis using FlowJo X was used to exclude PI positive cells and to graph the cells 
positive for green (FL-1) fluorescence. Mean green fluorescence was calculated with FlowJo X.
CellROX® Deep Red Assay. SH-SY5Y cells were seeded at 6.25 × 104 cells/cm2 on 13 mm coverslips. 
24 hours later cells were incubated with 10 μM CellROX® Deep Red (Life Technologies) and 2.8 μg/ml Hoechst 
33342 (Fluka) for 30 minutes. CellROX® and Hoechst 33342 were removed and cells were washed three times 
with complete medium. Proxison (10 μM) or DMSO vehicle was added for 30 minutes, and then 400 μM tBHP 
was added. One hour after tBHP addition, the coverslips were placed into an Attofluor® Cell Chamber (Life 
Technologies) holder and washed with Hank’s balanced salt solution (HBSS) with calcium and magnesium. 
Images were taken on the Zeiss Observer of phase contrast, CellROX® Deep Red and Hoechst 33342 fluorescence. 
Random areas (n = 5–6) of each coverslip were imaged. Post-acquisition analysis was performed using Volocity. A 
small area around each apparent cell nuclei was selected in all images and the mean fluorescence in arbitrary units 
(au) in these areas was calculated. The mean and standard error of mean (SEM) was calculated (n = 4).
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Immunocytochemistry and quantification. SH-SY5Y cells were seeded at 1.25 × 105 cells/cm2 on 
coverslips and incubated for 24 hours prior to addition of Proxison or vehicle (DMSO) for 30 minutes. Then 
400 μM tBHP was added for 4.5 hours when cells were fixed with 4% PFA for 20 minutes and washed three times 
with PBS. Immunocytochemistry was performed by the addition of blocking buffer (0.1% Triton X-100 or 0.3% 
Triton-X100 for nuclear staining, 2% goat serum, PBS) for 30 minutes. Primary antibodies rabbit IgG NRF2 
(1:800, C-20, Santa Cruz), mouse IgG2b 8-OHdG (1:1000, 15A3, abcam) in blocking buffer were added to cells 
for 16 hours at 4 °C, when they were washed 3 times in PBS with 0.1% Triton X-100. Secondary antibodies (Life 
Technologies) in blocking buffer were incubated with cells for 2 hours at room temperature in the dark, when they 
were washed 3 times in PBS with 0.1% Triton X-100. DAPI (10–50 μg/ml, Life Technologies) in PBS was added 
for 10 minutes. Cells were imaged using Leica TCS SPE confocal microscope. NRF2 images were quantified using 
ImageJ. The z-stack images were flattened and a mask was created using the DAPI channel. This mask was then 
used to calculate the nuclear red fluorescence intensity. The mean fluorescence from each image (2–4 images) and 
from each coverslip was calculated. The 8-OHdG images were quantified using ImageJ. The z-stack images were 
flattened and a mask was created using the DAPI channel, this mask included the nuclei and the area surrounding 
the nuclei by reducing the threshold. This mask was then used to calculate the nuclear green fluorescence inten-
sity. The mean fluorescence from each image was calculated with ImageJ.
RT-qPCR. SH-SY5Y cells were loaded with Proxison or DMSO as a control for 30 minutes before 400 μM 
tBHP was added for 4.5 hours when cells were lifted with trypsin and pelleted. RNA extraction was performed 
using the Epicentre MasterPure™ Complete DNA and RNA Purification Kit (Epicentre, MC85200), according 
to manufacturer’s instructions. RNA concentration was quantified using a Nanodrop spectrophotometer. Total 
RNA (1 μg) was used for cDNA synthesis. RNase-free water was added to the RNA to give a 10 μl sample. The 
samples were incubated with 1 μl dNTP mix (10 mM Life Technologies) and 1 μl random primers (50 ng/μl, 
Thermo Fisher) at 65 °C for 5 minutes and then chilled on ice. After brief centrifugation, 4 μl 5x First strand buffer 
(Life Technologies), 2 μl 0.1 M DTT (Life Technologies) and 1 μl RNAse OUT (40 units/μl, Life Technologies) 
were added. The contents was incubated at 37 °C for 2 minutes. Then 1 μl M-MLV reverse transcriptase (200 
units/μl, Life Technologies) or 1 μl RNase-free water for the negative reverse transcriptase sample was added. 
This was mixed and incubated at room temperature for 10 minutes when it was moved to 37 °C for 60 min-
utes. The reaction was inactivated by incubation at 90 °C for 10 minutes. The cDNA mix was placed on ice and 
80 μl RNase-free water was added. qPCR was performed using the Roche LightCycler® 480 System with the 
Universal Probe Library (UPL) (Roche). The Roche UPL Assay design centre was used to design intron-spanning 
primers with a specific UPL probe for each gene (TBP F-gaacatcatggatcagaacaaca R-atagggattccgggagtcat 
Probe 87; NRF2 F-acacggtccacagctcatc R-tgcctccaaagtatgtcaatca Probe 18; HMOX1 F-cagtcaggcagagggtgatag 
R-agctcctgcaactcctcaaa Probe 42; NQO1 F-acgctgccatgtatgacaaa R-ggatcccttgcagagagtaca Probe 9). Reactions 
(10 μl) containing primers, UPL Probe, LightCycle® 480 Probes Master mix (Roche) and PCR water were per-
formed in 386-well plates as described in the manufacturer’s instructions. The results were normalized to RNA 
levels of TATA-binding protein (TBP).
Treatment of zebrafish embryos with 6-hydroxydopamine (6-OHDA) and neuroprotective com-
pounds. All zebrafish were maintained under Home Office Project Licence No.: 60/4196 and all experiments 
were performed in accordance with the relevant guidelines and regulations, and approved by the Animal Welfare 
and Ethical Review Body of the University of Edinburgh. The Wik wild-type strain of zebrafish was used for this 
study, and they were maintained in standard conditions59. Clutches of embryos were obtained from single pair 
matings to ensure all embryos were at the same developmental stage across treatments. At 24 hours post fertilisa-
tion (hpf) embryos were split into groups of 24–30 embryos and treated with 250 µM 6-OHDA (162957, Sigma) 
or 250 µM 6-OHDA + 10 µM Proxison or quercetin in 3 ml embryo medium for 24 hours (water for control). At 
48 hpf embryos were fixed in 4% paraformaldehyde in PBS for 45 min. Samples were then blocked (2% bovine 
serum in 0.1% PBS-triton) for 1 h at room temperature. A mouse monoclonal anti-TH antibody (1:1000 diluted in 
blocking buffer, MAB318, Millipore) was used as the primary antibody and incubated with the samples overnight 
at 4 °C. The next day samples were washed in 0.1% PBS-T, followed by incubation with a secondary antibody Cy3 
donkey α-mouse IgG (1:200 diluted in blocking buffer, 715165150, Jackson Immuno) overnight at 4 °C. Samples 
were then washed and mounted in 70% glycerol in PBS. Embryos were imaged by confocal microscopy (LSM710, 
Zeiss, Oberkochen, Germany), and Z-stacks were taken through the head ensuring all cells could be quantified. 
Cell counts were performed using ImageJ. The observer was blinded for all quantifications of confocal images.
Statistical Analysis and Raw Data. Statistical Analysis was performed in Minitab using the Analysis of 
Variance (ANOVA) statistical test with a Tukey’s post-hoc test. Raw data used to generate all graphs can be found 
at LabArchives DOI 10.6070/H44X55WM.
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